225 related articles for article (PubMed ID: 19508832)
1. Investigational agents in the management of non-small cell lung cancer.
Pennell NA; Mekhail T
Curr Oncol Rep; 2009 Jul; 11(4):275-84. PubMed ID: 19508832
[TBL] [Abstract][Full Text] [Related]
2. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
[TBL] [Abstract][Full Text] [Related]
3. Newer opportunities in systemic therapy of lung cancer.
Rajan A; Gutierrez M; Giaccone G
Ann Oncol; 2008 Sep; 19 Suppl 7(Suppl 7):vii31-7. PubMed ID: 18790973
[No Abstract] [Full Text] [Related]
4. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Pakkala S; Ramalingam SS
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
7. New insights in drug development for the non-small cell lung cancer therapy.
Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
[TBL] [Abstract][Full Text] [Related]
8. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
9. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
10. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Wheler J; Falchook G; Tsimberidou AM; Hong D; Naing A; Piha-Paul S; Chen SS; Heymach J; Fu S; Stephen B; Fok JY; Janku F; Kurzrock R
Oncotarget; 2013 May; 4(5):772-84. PubMed ID: 23800712
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
12. Salvage with erlotinib plus bevacizumab: not in NSCLC.
Sculier JP; Meert AP; Berghmans T
Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
[No Abstract] [Full Text] [Related]
13. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Falchook GS; Naing A; Hong DS; Zinner R; Fu S; Piha-Paul SA; Tsimberidou AM; Morgan-Linnell SK; Jiang Y; Bastida C; Wheler JJ; Kurzrock R
Oncotarget; 2013 Jan; 4(1):118-27. PubMed ID: 23435217
[TBL] [Abstract][Full Text] [Related]
14. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Li H; Takayama K; Wang S; Shiraishi Y; Gotanda K; Harada T; Furuyama K; Iwama E; Ieiri I; Okamoto I; Nakanishi Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1297-305. PubMed ID: 25344762
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
17. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
[TBL] [Abstract][Full Text] [Related]
18. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
19. [Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
[TBL] [Abstract][Full Text] [Related]
20. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]